SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Author:
Funder
AstraZeneca Schweiz
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
https://link.springer.com/content/pdf/10.1007/s00262-020-02757-8.pdf
Reference37 articles.
1. Paterson AM, Brown KE, Keir ME et al (2011) The programmed death-1 ligand 1: B7–1 pathway restrains diabetogenic effector T cells in vivo. J Immunol 187:1097–1105
2. Johnson DH, Schiller JH, Bunn JP (2014) Recent clinical advances in lung cancer management. J Clin Oncol 32:973–982
3. Reck M, Rodríguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37:537–546. https://doi.org/10.1200/jco.18.00149
4. Spigel D, De Marinis F, Giaccone G et al (2019) IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. Ann Oncol 30:v915
5. Govindan R, Garfield DH (2004) Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 31(Suppl 11):27–31. https://doi.org/10.1053/j.seminoncol.2004.10.006
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17;European Journal of Cancer;2024-03
2. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2;eClinicalMedicine;2023-12
3. Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?;International Journal of Molecular Sciences;2023-08-09
4. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study;The Lancet;2023-08
5. Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study;JTO Clinical and Research Reports;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3